The Mediating Role of Emotional Eating and Sleep Quality in the Relationship Between Mental State and Metabolic Syndrome in Individuals With Schizophrenia and Bipolar Disorder
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 78
- Locations
- 1
- Primary Endpoint
- Metabolic Syndrome Risk
Study Overview
Brief Summary
In predominantly medication-naïve schizophrenic patients, those exhibiting partial metabolic disorders have significantly worse sleep quality and sleep onset time; poor sleep predicted metabolic dysregulation even after controlling for confounding factors. Mental health, sleep, and eating behavior interact in ways that strongly influence the risk of obesity and MetS. Emotional eating (eating in response to emotions rather than hunger) is central to this network and appears to be closely associated with psychiatric illnesses, particularly depression, anxiety, and sleep disorders. There is a continuing need to elucidate the frequency, level, and relationship of emotional eating with other factors in individuals with SMI. Therefore, this study aims to elucidate this complex relationship, thereby shedding light on new ways to reduce metabolic risks in psychiatric patients.
Detailed Description
Research Questions
- Is there a relationship between mental status and MetS in individuals with SMI?
- How does diagnosis (schizophrenia or bipolar disorder) and the group of medications used affect MetS in individuals with SMI?
- What is the level of emotional eating in individuals with SMI?
- Do emotional eating and sleep quality affect MetS in relation to mental status in individuals with SMI?
Hypotheses
H1 The group of psychotropic medications routinely used significantly affects MetS levels.
H2 Individuals with SMI have high levels of emotional eating.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Cross Sectional
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Being registered with the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center,
- •Having a severe chronic psychiatric illness (Schizophrenia Spectrum and Other Psychotic Disorders and Bipolar Disorder) followed by the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center for at least 6 months,
- •Being in remission (Complete Remission (Pre-Remission): Symptoms remaining below threshold values for at least 2 months (8 weeks). A state of improvement lasting more than 2 months is generally referred to as "remission"),
- •Schizophrenia remission definition: 8 diagnostically significant symptoms were selected from the Positive and Negative Syndrome Scale.
- •Bipolar disorder remission definition: Complete remission is defined as the absence of acute attacks and the presence of minimal/very mild symptoms.
- •Being between 18-65 years of age,
- •Being able to understand what is read and give written consent.
Exclusion Criteria
- •clusion Criteria:
- •Having a diagnosis of mental retardation,
- •Having other neurocognitive disorders, primarily dementia, according to DSM-V (as it can affect the ability to make decisions and give correct answers),
- •Not being able to speak or understand Turkish.
Outcomes
Primary Outcomes
Metabolic Syndrome Risk
Time Frame: Baseline
Participants' current metabolic syndrome risk scores will be measured using the Metabolic Syndrome Risk Index. The total score ranges from 0 to 100. A higher score indicates a higher risk of metabolic syndrome risk.
Secondary Outcomes
- Emotional eating level(Baseline)
- Sleep quality(Baseline)
- Positive and negative symptom(Baseline)
- Manic symptom(Baseline)
- Depressive symptoms(Baseline)
Investigators
Melisa BULUT
Research Assistant PhD
Abant Izzet Baysal University